Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Humans
Meningioma
/ diagnostic imaging
Receptors, Somatostatin
/ metabolism
Gallium Radioisotopes
Reproducibility of Results
Octreotide
/ therapeutic use
Positron-Emission Tomography
Meningeal Neoplasms
/ diagnostic imaging
Organometallic Compounds
/ therapeutic use
Neuroendocrine Tumors
/ pathology
68Gallium-DOTA(0)-Tyr(3)-octreotide
Lutetium Lu 177 dotatate
Meningioma
Radiometry
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
02
11
2022
accepted:
12
03
2023
revised:
10
02
2023
medline:
21
9
2023
pubmed:
6
5
2023
entrez:
6
5
2023
Statut:
ppublish
Résumé
Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by Thirty-nine meningioma lesions from twenty patients were analyzed. The ground truth PET and SPECT volumes (Vol Vol Accurate definition of pretherapeutic PET volumes is justified since SUV SUV • SUV
Identifiants
pubmed: 37148355
doi: 10.1007/s00330-023-09697-8
pii: 10.1007/s00330-023-09697-8
doi:
Substances chimiques
Receptors, Somatostatin
0
Gallium Radioisotopes
0
Octreotide
RWM8CCW8GP
Organometallic Compounds
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7089-7098Informations de copyright
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Références
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 22:iv1–iv96
doi: 10.1093/neuonc/noaa200
pubmed: 33123732
pmcid: 7596247
Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821–1834
doi: 10.1093/neuonc/noab150
pubmed: 34181733
pmcid: 8563316
Kaley T, Barani I, Chamberlain M et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 16:829–840
doi: 10.1093/neuonc/not330
pubmed: 24500419
pmcid: 4022224
Rachinger W, Stoecklein VM, Terpolilli NA et al (2015) Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med 56:347–353
doi: 10.2967/jnumed.114.149120
pubmed: 25635133
Mirian C, Duun-Henriksen AK, Maier A et al (2021) Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: individual patient data meta-analysis. J Nucl Med 62:507–513
doi: 10.2967/jnumed.120.249607
pubmed: 32859705
Seystahl K, Stoecklein V, Schüller U et al (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 18:1538–1547
pubmed: 27106404
pmcid: 5063513
Ilan E, Sandström M, Wassberg C et al (2015) Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med 56:177–182
doi: 10.2967/jnumed.114.148437
pubmed: 25593115
Sundlöv A, Sjögreen-Gleisner K, Svensson J et al (2017) Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging 44:1480–1489
doi: 10.1007/s00259-017-3678-4
pubmed: 28331954
pmcid: 5506097
Hänscheid H, Sweeney RA, Flentje M et al (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284–1288
doi: 10.1007/s00259-012-2124-x
pubmed: 22526964
SjögreenGleisner K, Chouin N, Gabina PM et al (2022) EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging 49:1778–1809
doi: 10.1007/s00259-022-05727-7
Gustafsson J, Sundlöv A, Sjögreen Gleisner K (2017) SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy. EJNMMI Res 7:18
doi: 10.1186/s13550-017-0262-7
pubmed: 28233160
pmcid: 5323339
Zhan B, Xiao J, Cao C et al (2022) Multi-constraint generative adversarial network for dose prediction in radiotherapy. Med Image Anal 77:102339
doi: 10.1016/j.media.2021.102339
pubmed: 34990905
Li H, Peng X, Zeng J et al (2022) Explainable attention guided adversarial deep network for 3D radiotherapy dose distribution prediction. Knowl-Based Syst 241:108324
doi: 10.1016/j.knosys.2022.108324
Tan S, Tang P, Peng X et al (2021) Incorporating isodose lines and gradient information via multi-task learning for dose prediction in radiotherapy. In: de Bruijne M, Cattin PC, Cotin S et al (2021) Medical Image Computing and Computer Assisted Intervention – MICCAI 2021. Cham: Springer International Publishing 753–763.
Huang RY, Bi WL, Weller M et al (2019) Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 21:26–36
doi: 10.1093/neuonc/noy137
pubmed: 30137421
Kennedy JA, Lugassi R, Gill R, Keidar Z (2020) Digital solid-state SPECT/CT quantitation of absolute 177Lu radiotracer concentration: in vivo and in vitro validation. J Nucl Med 61:1381–1387
doi: 10.2967/jnumed.119.239277
pubmed: 32111686
Chevalier E, Boursier C, Claudin M, Marie P-Y, Imbert L (2020) Feasibility of 177Lu therapy monitoring using fast whole-body SPECT recordings provided by a high-speed 360° CZT camera. Clin Nucl Med 45:e493–e494
doi: 10.1097/RLU.0000000000003169
pubmed: 32604119
de Nijs R, Lagerburg V, Klausen TL, Holm S (2014) Improving quantitative dosimetry in (177)Lu-DOTATATE SPECT by energy window-based scatter corrections. Nucl Med Commun 35:522–533
doi: 10.1097/MNM.0000000000000079
pubmed: 24525900
pmcid: 3969156
Warfield SK, Zou KH, Wells WM (2004) Simultaneous Truth and Performance Level Estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging 23:903–921
doi: 10.1109/TMI.2004.828354
pubmed: 15250643
pmcid: 1283110
Perlow HK, Siedow M, Gokun Y et al (2022) 68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for patients with meningioma. Int J Radiat Oncol Biol Phys 113:859–865
doi: 10.1016/j.ijrobp.2022.04.009
pubmed: 35460804
Kriwanek F, Ulbrich L, Lechner W et al (2022) Impact of SSTR PET on inter-observer variability of target delineation of meningioma and the possibility of using threshold-based segmentations in radiation oncology. Cancers (Basel) 14:4435
Maclean J, Fersht N, Sullivan K et al (2017) Simultaneous 68Ga DOTATATE positron emission tomography/magnetic resonance imaging in meningioma target contouring: feasibility and impact upon interobserver variability versus positron emission tomography/computed tomography and computed tomography/magnetic resonance imaging. Clin Oncol (R Coll Radiol) 29:448–458
doi: 10.1016/j.clon.2017.03.004
pubmed: 28433399
Pelak MJ, Flechl B, Mumot M et al (2021) The value of SSTR2 receptor-targeted PET/CT in proton irradiation of grade I meningioma. Cancers 13:4707
doi: 10.3390/cancers13184707
pubmed: 34572933
pmcid: 8469658
Jentzen W (2015) An improved iterative thresholding method to delineate PET volumes using the delineation-averaged signal instead of the enclosed maximum signal. J Nucl Med Technol 43:28–35
doi: 10.2967/jnmt.114.152678
pubmed: 25655341
Kolinger GD, García DV, Kramer GM et al (2022) Effects of tracer uptake time in non–small cell lung cancer
doi: 10.2967/jnumed.121.262660
pubmed: 34933890
pmcid: 9157719
Werner-Wasik M, Nelson AD, Choi W et al (2012) What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 82:1164–1171
doi: 10.1016/j.ijrobp.2010.12.055
pubmed: 21531085
Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78:4786–4789
doi: 10.1158/0008-5472.CAN-18-0125
pubmed: 29959149
Wales DJ, Doye JPK (1997) Global optimization by basin-hopping and the lowest energy structures of Lennard-Jones clusters containing up to 110 atoms. J Phys Chem A 101:5111–5116
doi: 10.1021/jp970984n
Hastie T, Tibshirani R, Friedman J (2009) The elements of statistical learning. available via : http://link.springer.com/10.1007/978-0-387-84858-7 . Accessed 01 Feb 2023
Menze BH, Jakab A, Bauer S et al (2015) The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging 34:1993–2024
doi: 10.1109/TMI.2014.2377694
pubmed: 25494501
Galldiks N, Albert NL, Sommerauer M et al (2017) PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol 19:1576–1587
doi: 10.1093/neuonc/nox112
pubmed: 28605532
pmcid: 5716194
O’Donoghue JA, Bardiès M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909
pubmed: 7562062
Peters SMB, Hofferber R, Privé BM et al (2022) [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging 49:1101–1112
doi: 10.1007/s00259-021-05538-2
pubmed: 34623453
Le Van T, Graillon T, Jacob J et al (2021) Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. J Neurooncol 153:55–64
doi: 10.1007/s11060-021-03741-7
pubmed: 33778930
Salgues B, Graillon T, Horowitz T et al (2022) Somatostatin receptor theranostics for refractory meningiomas. Curr Oncol 29:5550–5565
doi: 10.3390/curroncol29080438
pubmed: 36005176
pmcid: 9406720
van Essen M, Krenning EP, Kooij PP et al (2006) Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47:1599–1606
pubmed: 17015894
Müther M, Roll W, Brokinkel B et al (2020) Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin 59:348–355
doi: 10.1055/a-1200-0989
pubmed: 32691404
Parghane RV, Talole S, Basu S (2019) Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J Nucl Med 18:160–170
doi: 10.4103/wjnm.wjnm_39_18
pubmed: 31040748
pmcid: 6476244
Marincek N, Radojewski P, Dumont RA et al (2015) Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med 56:171–176
doi: 10.2967/jnumed.114.147256
pubmed: 25593116
Minczeles NS, Bos EM, de Leeuw RC et al (2022) Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-022-06044-9
doi: 10.1007/s00259-022-06044-9
pubmed: 36454268
pmcid: 9250460
Verger A, Kas A, Darcourt J, Guedj E (2022) PET imaging in neuro-oncology: an update and overview of a rapidly growing area. Cancers (Basel) 14:1103
doi: 10.3390/cancers14051103
pubmed: 35267411